Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504579 · ClinicalTrials.gov registry record · NA
Rt-fMRI Neurofeedback and AH in Schizophrenia
A NA study of Schizophrenia and Neurofeedback, sponsored by Harvard Medical School (HMS and HSDM).
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03504579: Completed NA study of Schizophrenia and Neurofeedback, sponsored by Harvard Medical School (HMS and HSDM).
NCT03504579 is a NA study of Schizophrenia and Neurofeedback that has completed, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 25 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03504579, a NA study of Schizophrenia and Neurofeedback, has completed, sponsored by Harvard Medical School (HMS and HSDM).
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Auditory hallucinations in schizophrenia are one of the major symptoms of this disease and a major source of psychological discomfort. They are often difficult or impossible to treat with existing methods. This study will test the use of real-time fMRI neurofeedback to mitigate auditory verbal hallucinations in patients whose hallucinations are resistant to medication. Half of the patients will receive real time fMRI neurofeedback from a brain region involved in auditory hallucinations and half will receive it from motor cortex.
Primary Outcome
changes in BOLD activation in STG
Conditions Studied
Interventions
- OTHER rt-fMRI neurofeedback
Study Locations (1)
Massachusetts
- Veterans Administration Health Care System - Brockton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
What the finished NCT03504579 record still lists
NCT03504579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (89% lower).
The record links to 4 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which rt-fMRI neurofeedback is the first listed.
NCT03504579 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03504579 about?
NCT03504579 is a clinical study titled "Rt-fMRI Neurofeedback and AH in Schizophrenia". Auditory hallucinations in schizophrenia are one of the major symptoms of this disease and a major source of psychological discomfort. They are often difficult or impossible to treat with existing methods. This study will test the use of real-time fMRI neurofeedback to mitigate auditory verbal hallu...
What is the current status of trial NCT03504579?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2018-03-01. Estimated completion is 2022-06-30.
What conditions does trial NCT03504579 study?
This clinical trial studies the following conditions: Schizophrenia, Neurofeedback, Audio Visual Hallucinations, Superior Temporal Gyrus.
What interventions are being tested in trial NCT03504579?
The interventions under investigation include: rt-fMRI neurofeedback (OTHER).
Who is sponsoring clinical trial NCT03504579?
This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03504579 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03504579's enrollment target sits among peer trials
25 272nd of 315 higher than 41 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI